Last week, the Federal Trade Commission (FTC) approved the $40.5 billion acquisition of Allergan's generic drugs business by Israel-based company, Teva Pharmaceuticals. In order to receive the FTC's support with the deal, Teva agreed to unload 79 generic products onto 11 different companies. While Teva was already a top generics maker in many markets before the deal with Allergan, the company now expects to be in the top three in more than 40 markets worldwide. The company expects that in the next three years, the acquisition will generate more than $25 billion in revenue. "The new Teva will be ideally positioned to realize the opportunities the global and U.S. generic markets offer," said Erez Vigodman, chief executive of Teva. According to the FTC, Teva will soon take control of a 22 percent market share in the US. "Although this merger combines two large sellers of generic drugs, the generic pharmaceutical industry as a whole remains relatively unconcentrated," said a statement issued by the FTC.